Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jan 15, 2021 7:03pm
350 Views
Post# 32311883

Why did they do this horrible offering?

Why did they do this horrible offering?WIth the selling after hours, it is hard not to add some paranoia to the stages of grief we ae dealign with already. So, does anyone have a decent theory about why an otherwise sensible group of people who clearly know better than to issue shares on such awful terms went ahead  and did so anyway? Here is my offerings on that but I must not be seeing something and I hope someone else will:

1.) The easist explanation is they have been wanting to do this for a while and thought the bubble was about to burst, potentially cutting off funding for a while. Given that share sales were going on hot and heavy last April at the height of the covid panic, however, that would seem to be a big overreaction to a possible scenario that may not materialize for a while.  

2.) When reading the prospectus, it is perfectly clear they are having an issue getting the EMA on board. They are still "assessing their strategy" regarding the EMA  according to the prospectus and since they have had so much time to interact with them already, that can only mean there is a high probability of the EMA not giving TH a thumbs up on the phase III. With questions still looming at the FDA, they knew that could call the whole NASH program into question in investors minds and wanted to raise money while everyone still thought all was well on the NASH phase III front. That would be quite a deception but the way things went down with the deal being announced just 2 days after the "good news" on the FDA letter, with no US brokers involved, and on horrible terms led by a second tier Canadian briker, it sure smells like that.

We had said that it was key for Paul and the company to get this phase III thing done or their credibility would be mud. Perhaps this is why they moved to raise money in this atrocious way since they knew their credibility would soon be in tatters?


<< Previous
Bullboard Posts
Next >>